Gbènankpon Mathias Houvèssou1, Simone Farías-Antúnez2, Mariângela Freitas da Silveira3. 1. Postgraduate Program in Epidemiology, Federal University of Pelotas, RS, Brazil. Electronic address: gbemathg@gmail.com. 2. Postgraduate Program in Epidemiology, Federal University of Pelotas, RS, Brazil. 3. Postgraduate Program in Epidemiology, Federal University of Pelotas, RS, Brazil. Electronic address: mariangelafreitassilveira@gmail.com.
Abstract
INTRODUCTION: Combined hormonal contraceptives (CHC), containing estrogen, remain the most popular choice of contraceptive among women. While the method offers many benefits, the use of CHC involves potential health risks. The aim of this study was to analyze the available evidence on the prevalence of CHC use among women with contraindications to their use according to the WHO recommendations (2015). METHODS: Pubmed, Lilacs, and Web of Sciences databases were searched. Selection was based on articles that described the use of combined hormonal contraceptives according to the characteristics that are listed as contraindications in WHO medical eligibility criteria for contraceptive use. RESULTS: A total of 4363 articles were identified and 18 articles were selected for the review. The most prevalent contraindications against use of CHC were systemic arterial hypertension, migraine, and smoking (in women aged 35 years or older). Prevalence rates of contraindications against use of CHC ranged from 5.9% to 41.9%. CONCLUSIONS: A high proportion of women still use CHC when contraindicated to do so according to the WHO criteria. Health policies should focus on highlighting the importance of a detailed health evaluation on CHC candidates, to reduce the proportion of inappropriate prescriptions.
INTRODUCTION: Combined hormonal contraceptives (CHC), containing estrogen, remain the most popular choice of contraceptive among women. While the method offers many benefits, the use of CHC involves potential health risks. The aim of this study was to analyze the available evidence on the prevalence of CHC use among women with contraindications to their use according to the WHO recommendations (2015). METHODS: Pubmed, Lilacs, and Web of Sciences databases were searched. Selection was based on articles that described the use of combined hormonal contraceptives according to the characteristics that are listed as contraindications in WHO medical eligibility criteria for contraceptive use. RESULTS: A total of 4363 articles were identified and 18 articles were selected for the review. The most prevalent contraindications against use of CHC were systemic arterial hypertension, migraine, and smoking (in women aged 35 years or older). Prevalence rates of contraindications against use of CHC ranged from 5.9% to 41.9%. CONCLUSIONS: A high proportion of women still use CHC when contraindicated to do so according to the WHO criteria. Health policies should focus on highlighting the importance of a detailed health evaluation on CHC candidates, to reduce the proportion of inappropriate prescriptions.
Authors: Ghadah A Assiri; Douha F Bannan; Ghadah H Alshehri; Manal Alshyhani; Walaa Almatri; Mansour A Mahmoud Journal: Int J Environ Res Public Health Date: 2022-01-29 Impact factor: 3.390